200,000+ products from a single source!
sales@angenechem.com
96420-76-7 | sodium naphthalene-2-sulfonate formaldehyde(1:1:1)
CAS No: 96420-76-7 Catalog No: AG006RLL MDL No:
Product Description
Catalog Number:
AG006RLL
Chemical Name:
sodium naphthalene-2-sulfonate formaldehyde(1:1:1)
CAS Number:
96420-76-7
Molecular Formula:
C11H9NaO4S
Molecular Weight:
260.2415
IUPAC Name:
sodium;formaldehyde;naphthalene-2-sulfonate
InChI:
InChI=1S/C10H8O3S.CH2O.Na/c11-14(12,13)10-6-5-8-3-1-2-4-9(8)7-10;1-2;/h1-7H,(H,11,12,13);1H2;/q;;+1/p-1
InChI Key:
ZRGAGHDXHBGIJK-UHFFFAOYSA-M
SMILES:
[O-]S(=O)(=O)c1ccc2c(c1)cccc2.C=O.[Na+]
EC Number:
609-228-0
Properties
Complexity:
298
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
3
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
260.012g/mol
Formal Charge:
0
Heavy Atom Count:
17
Hydrogen Bond Acceptor Count:
4
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
260.239g/mol
Monoisotopic Mass:
260.012g/mol
Rotatable Bond Count:
1
Topological Polar Surface Area:
82.6A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Topical microbicides for prevention of sexually transmitted infections. | The Cochrane database of systematic reviews 20120613 |
| A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment. | PloS one 20110101 |
| 'One teabag is better than four': Participants response to the discontinuation of 2% PRO2000/5 microbicide gel in KwaZulu-Natal, South Africa. | PloS one 20110101 |
| Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety. | PloS one 20110101 |
| PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. | Lancet (London, England) 20101016 |
| Preventing HIV infection: turning the tide for young women. | Lancet (London, England) 20101016 |
| Current drugs in clinical study. | Project Inform perspective 20100201 |
| Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. | The Journal of infectious diseases 20090815 |
| Enhancement of human immunodeficiency virus type 1 replication is not intrinsic to all polyanion-based microbicides. | Antimicrobial agents and chemotherapy 20090801 |
| Human glutaredoxin-1 catalyzes the reduction of HIV-1 gp120 and CD4 disulfides and its inhibition reduces HIV-1 replication. | The international journal of biochemistry & cell biology 20090601 |
| HIV-1 infection of human penile explant tissue and protection by candidate microbicides. | AIDS (London, England) 20090128 |
| Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention. | Trials 20090101 |
| Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. | Antiviral therapy 20090101 |
| Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides. | Antiviral research 20070901 |
| PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. | AIDS (London, England) 20070219 |
| Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. | Retrovirology 20060101 |
| Effects of candidate vaginally-applied microbicide compounds on innate immune cells. | Journal of reproductive immunology 20050801 |
| Effect of candidate vaginally-applied microbicide compounds on recognition of antigen by CD4+ and CD8+ T lymphocytes. | Biology of reproduction 20041101 |
| Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. | The Journal of infectious diseases 20040201 |
| 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. | AIDS (London, England) 20010817 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.